Peptide Companion
Back to catalog
Peptide Companion
single
Sleep
Vial: 2 mg

CJC-1295 DAC (2 mg Vial)

CJC-1295 DAC dosage protocols leverage this long-acting growth hormone-releasing hormone (GHRH) analog’s unique albumin-binding technology, which extends its half-life to approximately 6–8 days. By stimulating pulsatile growth hormone (GH) release while preserving natural GH rhythms, CJC-1295 DAC can elevate GH levels 2–10 fold and IGF-1 levels 1.5–3 fold in human studies. Benefits may include enhanced muscle growth and recovery, improved fat metabolism, better sleep quality, and anti-aging effects through sustained GH/IGF-1 axis activation. This educational protocol presents a once-weekly subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Dose
1–2 mg per week
Frequency
Once weekly
Timing
Before bed
Duration
8–12 weeks minimum

Long-acting GH secretagogue. Provides sustained GH elevation. Often combined with Ipamorelin.

Dosing Schedule
WeekWeekly Dose (mcg)Units (per injection) (mL)
Weeks 1–122,000 mcg (2 mg)100 units (1.00 mL)
Supplies Needed
  • •Peptide Vials (CJC-1295 DAC, 2 mg each):
  • •Insulin Syringes (U-100, 1 mL capacity):
  • •Bacteriostatic Water (10 mL bottles): Use 1.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each week.
References

  • Journal of Clinical Endocrinology & Metabolism

    Prolonged stimulation of GH and IGF-1 secretion by CJC-1295 in healthy adults

    View source

  • Clinical Pharmacology & Therapeutics

    DAC technology: albumin-binding for extended peptide half-life

    View source

  • Journal of Clinical Endocrinology & Metabolism

    Single and multiple dose pharmacokinetics of CJC-1295 in healthy subjects

    View source

  • Growth Hormone & IGF Research (ScienceDirect)

    Activation of the GH/IGF-1 axis by CJC-1295 and serum protein profile changes

    View source

  • PubMed

    Body composition and quality of life in adults with GH deficiency; effects of GH replacement

    View source

  • PubMed

    Physiology of growth hormone secretion during sleep

    View source

  • Journal of Clinical Endocrinology & Metabolism

    Safety and tolerability of CJC-1295 at various dose levels in healthy subjects

    View source

  • Bachem

    Handling and storage guidelines for peptides

    View source

  • CDC

    Preventing unsafe injection practices and clinical safety guidelines

    View source

  • MedlinePlus

    Subcutaneous (SQ) injections: technique, site selection, and rotation

    View source

  • Endocrine Reviews

    GHRH analogs and preservation of pulsatile GH secretion patterns

    View source

  • PubMed

    Effect of tesamorelin on visceral fat in HIV-infected patients: randomized clinical trial

    View source

  • NIBSC

    Peptide storage recommendations and stability guidelines

    View source

Educational content adapted from peptidedosages.com. Not medical advice.